EUCTR2022-001282-12-BE进行中（未招募）1 期
A proof-of-concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients
ovadip Biosciences0 个研究点目标入组 4 人开始时间: 2022年5月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female pediatric patients:
- •a.Diagnosed with congenital pseudarthrosis of the tibia (with or without NF1) and presenting with a non-healing Paley type 3 or 4 fracture.
- •b.With a minimum weight of 5kg/11lbs.
- •c.Within the age range of 2 years to 8 years.
- •2.Maximum 2 previous failed surgical orthopedic interventions to treat the primary CPT fracture.
- •3.Patient fulfills criteria for undergoing a surgical intervention (ATC and GS) as per standard of care.
- •4.Patient has serology and molecular test results excluding the presence of Human T-cell lymphoma virus (HTLV1/2), human immunodeficiency virus (HIV 1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis
- •5.Possibility to obtain a minimum of 2cc/ 0.07fl.oz. (preferably up to 10cc/ 0.34fl oz) of adipose tissue.
- •6.Satisfactory general health condition to undergo surgeries (ATC and GS) with anesthesia as per local standards.
- •7.The fracture and patient baseline characteristics allow the application of a pre-defined standardized surgical procedure.
- •8.A NVD 003 graft volume need not exceeding 20cc (0.68fl oz), confirmed by the treating orthopedic surgeon based on radiological measurements. The estimated volume should cover the total of the residual tibial bone defect volume of 0.5 to 1cm (0.2 0.39in) in height, the cross-union tibial bone-fibula volume and the eventual fibular bone defect volume.
- •9.The patient’s parent(s) and/or legal guardian(s) provided written informed consent and accepted the participation of the patient in the trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Bilateral CPT.
- •2.Presence of CPT without a fracture of the tibia (Paley type 1 and 2).
- •3.More than 2 failed surgical attempt(s) to treat the primary tibial fracture.
- •4.Evidence of plexiform neurofibroma of any size or nodular fibroma = 1.2in/3cm on the ipsilateral leg.
- •5.Clinically significant infection at the target grafting site or systemic infection.
- •6.History of allergic reaction or any anticipated hypersensitivity to any anesthetic agent or any potential hypersensitivity to any of the components of the NVD-003 graft (including the CMRL1066 transport medium).
- •7.CPT fracture requiring the use of one of the following surgical techniques:
- •a.An external fixation system (e.g. Ilizarov, TSF, rail, …);
- •b.A carrier or scaffold;
- •c.An autogenous recombinant human bone morphogenetic protein.
- •8.Presence of clinically significant hematologic, renal, hepatic, and coagulation laboratory abnormalities (i.e., CBC, PT/INR, Chem-7, and LFTs, etc.).
- •9.Presence of any auto-immune disease, with exception of well controlled diabetes type 1 or auto-immune thyroid disorders.
- •10.Any history of experimental therapy with another investigational drug within 60 days prior to screening.
- •11.Presence of active tumor.
- •12.Documented metabolic bone disease or any disorder, such as but not limited to osteogenesis imperfecta and osteomalacia, that could interfere with the bone healing and bone metabolism.
- •13.Chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, anticoagulant therapies, immunosuppressant therapy or immunotherapy.
- •14.Patient was breastfed less than 1 year before the lipo-aspiration.
- •15.Any condition which, in the opinion of the investigator, could interfere with trial conduct, the patient’s compliance with the protocol or influence interpretation of the results.
研究者
相似试验
进行中（未招募）
1 期
A proof of concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients.Congenital pseudarthrosis of the tibiaCTIS2024-515478-29-00ovadip Biosciences4
进行中（未招募）
1 期
A first-in-human proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of distal radius fractures in adults.Distal radius fracturesCTIS2023-508321-27-00ovadip Biosciences10
进行中（未招募）
1 期
A proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of low grade degenerative lumbar spondylolisthesis by interbody spine fusion in adults.CTIS2023-508471-37-00ovadip Biosciences10
进行中（未招募）
1 期
Alginate encapsulated Stem Cell Transplantation study for Corneal diseases.CTRI/2021/07/035034Hyderabad Eye Research Foundation
进行中（未招募）
1 期
Clinical evaluation of Limbal Stromal Stem Cell for its safety and efficacy for treatment of corneal injuriesCTRI/2020/07/026891Hyderabad Eye Research Foundation